Sanofi | Lantus® | Insulin Glargine | Diabetes | Euro | 5,715 | 6,344 | 11.00% |
Sanofi | Apidra® | Insulin Glulisine | Diabetes | Euro | 288 | 336 | 16.70% |
Sanofi | Amaryl® | Glimepiride | Diabetes | Euro | 375 | 360 | -4.00% |
Sanofi | Insuman® | Insulin | Diabetes | Euro | 132 | 137 | 3.80% |
Sanofi | Blood Glucose Meters | | Diabetes | Euro | 48 | 64 | 33.30% |
Sanofi | Lyxumia® | Lixisenatide | Diabetes | Euro | 9 | 27 | 200.00% |
Sanofi | Other Products | | | Euro | 1 | 5 | 400.00% |
Sanofi | Total: Diabetes | | | Euro | 6,568 | 7,273 | 10.70% |
Sanofi | Jevtana® | Cabazitaxel | Oncology | Euro | 231 | 273 | 18.20% |
Sanofi | Taxotere® | Docetaxel | Oncology | Euro | 409 | 266 | -35.00% |
Sanofi | Thymoglobulin® | Anti-thymocyte Globulin | Immunology (Organ Transplant, Arthritis etc.) | Euro | 198 | 217 | 9.60% |
Sanofi | Eloxatin® | Oxaliplatin | Oncology | Euro | 221 | 210 | -5.00% |
Sanofi | Mozobil® | Plerixafor | Oncology | Euro | 101 | 111 | 9.90% |
Sanofi | Zaltrap® | Aflibercept | Oncology | Euro | 53 | 69 | 30.20% |
Sanofi | Other Products | | | Euro | 252 | 255 | 1.20% |
Sanofi | Total: Oncology | | | Euro | 1,465 | 1,401 | -4.40% |
Sanofi | Cerezyme® | Imiglucerase | Rare Disease | Euro | 688 | 715 | 3.90% |
Sanofi | Cerdelga® | Eliglustat | Rare Disease | Euro | - | 4 | |
Sanofi | Myozyme®/Lumizyme® | Alglucosidase alfa | Rare Disease | Euro | 500 | 542 | 8.40% |
Sanofi | Fabrazyme® | Agalsidase beta | Rare Disease | Euro | 383 | 460 | 20.10% |
Sanofi | Aldurazyme® | Laronidase | Rare Disease | Euro | 159 | 172 | 8.20% |
Sanofi | Other Products | | | Euro | 244 | 244 | 0.00% |
Sanofi | Sub-Total Rare Diseases | | | Euro | 1,974 | 2,137 | 8.30% |
Sanofi | Aubagio® | Teriflunomide | Neuroscience/Mental Health | Euro | 166 | 433 | 160.80% |
Sanofi | Lemtrada® | Alemtuzumab | Neuroscience/Mental Health | Euro | 2 | 34 | 1600.00% |
Sanofi | Sub-Total Multiple Sclerosis | | | Euro | 168 | 467 | 178.00% |
Sanofi | Total: Genzyme | | | Euro | 2,142 | 2,604 | 21.60% |
Sanofi | Plavix® | Clopidogrel Bisulfate | Cardiovascular | Euro | 1,857 | 1,862 | 0.30% |
Sanofi | Lovenox® | Enoxaparin Sodium | Anticoagulants | Euro | 1,703 | 1,699 | -0.20% |
Sanofi | Aprovel®/CoAprovel® | Irbesartan / Irbesartan+Hydrochlorothiazide | Antihypertensives | Euro | 882 | 727 | -17.60% |
Sanofi | Renagel®/Renvela® | Sevelamer Hydrochloride and Sevelamer Carbonate | Urology | Euro | 750 | 684 | -8.80% |
Sanofi | Depakine® | Valproate sodium | Neuroscience/Mental Health | Euro | 405 | 395 | -2.50% |
Sanofi | Synvisc®/Synvisc-One® | Hylan G-F 20 | Bone Health | Euro | 371 | 352 | -5.10% |
Sanofi | Stilnox®/Ambien®/Myslee® | Zolpidem | Sleep Disorders | Euro | 391 | 306 | -21.70% |
Sanofi | Multaq® | Dronedarone | Cardiovascular | Euro | 269 | 290 | 7.80% |
Sanofi | Tritace® | Ramipril | Antihypertensives | Euro | 307 | 281 | -8.50% |
Sanofi | Allegra® | Fexofenadine Hydrochoride | Respiratory Disorders | Euro | 406 | 192 | -52.70% |
Sanofi | Lasix® | Furosemide | Cardiovascular | Euro | 172 | 164 | -4.70% |
Sanofi | Targocid® | Teicoplanin | Anti-bacterial | Euro | 166 | 162 | -2.40% |
Sanofi | Orudis® | Ketoprofen | Bone Health | Euro | 144 | 160 | 11.10% |
Sanofi | Cordatone® | Amiodarone Hydrochloride | Cardiovascular | Euro | 141 | 129 | -8.50% |
Sanofi | Xatral® | Alfuzosin | Urology | Euro | 101 | 94 | -6.90% |
Sanofi | Actonel® | Risedronate sodium | Bone Health | Euro | 100 | 82 | -18.00% |
Sanofi | Auvi-Q®/Allerject® | Epinephrine | Cardiovascular | Euro | 60 | 72 | 20.00% |
Sanofi | Other Products | | | Euro | 4,221 | 3,649 | -13.60% |
Sanofi | Total: Other Prescription Products | | | Euro | 12,446 | 11,300 | -9.20% |
Sanofi | Consumer Health Care | | | Euro | 3,004 | 3,337 | 11.10% |
Sanofi | Generics | | | Euro | 1,625 | 1,805 | 11.10% |
Sanofi | Total Pharmaceuticals | | | Euro | 27,250 | 27,720 | 1.70% |
Sanofi | Contribution of Other Products | | | Euro | 4,718 | 4,153 | -12.00% |
Sanofi | Vaccine | | | Euro | 3,716 | 3,974 | 6.90% |
Sanofi | Animal Health | | | Euro | 1,985 | 2,076 | 4.60% |
Sanofi | Total Sales | | | Euro | 32,951 | 33,770 | 2.50% |
Johnson & Johnson | Remicade® | Infliximab | Immunology (Organ Transplant, Arthritis etc.) | USD | 6,673 | 6,868 | 2.90% |
Johnson & Johnson | Simponi®/Simponi Aria® | Golimumab | Immunology (Organ Transplant, Arthritis etc.) | USD | 932 | 1,187 | 27.40% |
Johnson & Johnson | Stelara® | Ustekinumab | | USD | 1,504 | 2,072 | 37.80% |
Johnson & Johnson | Other Products | | | USD | 81 | 66 | -18.50% |
Johnson & Johnson | Total: Immunology | | | USD | 9,190 | 10,193 | 10.90% |
Johnson & Johnson | Edurant® | Rilpivirine | Infectious Diseases (HIV, Hepatitis etc.) | USD | 236 | 365 | 54.70% |
Johnson & Johnson | Incivo® | Telaprevir | Infectious Diseases (HIV, Hepatitis etc.) | USD | 517 | 226 | -56.30% |
Johnson & Johnson | Olysio®/Sovriad® | Simeprevir | Infectious Diseases (HIV, Hepatitis etc.) | USD | 23 | 2,302 | 9908.70% |
Johnson & Johnson | Prezista® | Darunavir | Infectious Diseases (HIV, Hepatitis etc.) | USD | 1,673 | 1,831 | 9.40% |
Johnson & Johnson | Other Products | | | USD | 1,101 | 875 | -20.50% |
Johnson & Johnson | Total: Infectious Diseases | | | USD | 3,550 | 5,599 | 57.70% |
Johnson & Johnson | Concerta® / Methylphenidate | Methylphenidate | Neuroscience/Mental Health | USD | 782 | 599 | -23.40% |
Johnson & Johnson | Invega® | Paliperidone | Neuroscience/Mental Health | USD | 583 | 640 | 9.80% |
Johnson & Johnson | Invega® Sustenna® / Xeplion ® | Paliperidone Palmitate | Neuroscience/Mental Health | USD | 1,248 | 1,588 | 27.20% |
Johnson & Johnson | Risperdal ® Consta ® | Risperidone | Neuroscience/Mental Health | USD | 1,318 | 1,190 | -9.70% |
Johnson & Johnson | Other Products | | | USD | 2,736 | 2,470 | -9.70% |
Johnson & Johnson | Total: Neuroscience | | | USD | 6,667 | 6,487 | -2.70% |
Johnson & Johnson | Velcade® | Bortezomib | Oncology | USD | 1,660 | 1,618 | -2.50% |
Johnson & Johnson | Zytiga® | Abiraterone Acetate | Oncology | USD | 1,698 | 2,237 | 31.70% |
Johnson & Johnson | Other Products | | | USD | 415 | 602 | 45.10% |
Johnson & Johnson | Total: Oncology | | | USD | 3,773 | 4,457 | 18.10% |
Johnson & Johnson | Procrit® / Eprex® | Epoetin Alfa | Blood Related Disorders | USD | 1,364 | 1,238 | -9.20% |
Johnson & Johnson | Xarelto® | Rivaroxaban | Anticoagulants | USD | 864 | 1,522 | 76.20% |
Johnson & Johnson | Other Products | | | USD | 2,717 | 2,817 | 3.70% |
Johnson & Johnson | Total: Other Prescription Products | | | USD | 4,945 | 5,577 | 12.80% |
Johnson & Johnson | Contribution of Other Products | | | USD | 7,050 | 6,830 | -3.10% |
Johnson & Johnson | Total Pharmaceuticals | | | USD | 28,125 | 32,313 | 14.90% |
Johnson & Johnson | Consumer Health Care | | | USD | 14,697 | 14,496 | -1.40% |
Johnson & Johnson | Medical Devices | | | USD | 28,490 | 27,522 | -3.40% |
Johnson & Johnson | Total All Divisions | | | USD | 71,312 | 74,331 | 4.20% |
Bristol-Myers Squibb | Baraclude® | Entecavir | Infectious Diseases (HIV, Hepatitis etc.) | USD | 1,527 | 1,441 | -5.60% |
Bristol-Myers Squibb | Hepatits C Franchise | Daclatasvir and Asunaprevir | Infectious Diseases (HIV, Hepatitis etc.) | USD | - | 256 | |
Bristol-Myers Squibb | Reyataz® | Atazanavir Sulphate | Infectious Diseases (HIV, Hepatitis etc.) | USD | 1,551 | 1,362 | -12.20% |
Bristol-Myers Squibb | Sustiva® | Efavirenz | Infectious Diseases (HIV, Hepatitis etc.) | USD | 1,614 | 1,444 | -10.50% |
Bristol-Myers Squibb | Total: Virology | | | USD | 4,692 | 4,503 | -4.00% |
Bristol-Myers Squibb | Erbitux® | Cetuximab | Oncology | USD | 696 | 723 | 3.90% |
Bristol-Myers Squibb | Opdivo | Nivolumab | Oncology | USD | - | 6 | |
Bristol-Myers Squibb | Sprycel | Dasatinib | Oncology | USD | 1,280 | 1,493 | 16.60% |
Bristol-Myers Squibb | Yervoy | Ipilimumab | Oncology | USD | 960 | 1,308 | 36.30% |
Bristol-Myers Squibb | Total: Oncology | | | USD | 2,936 | 3,530 | 20.20% |
Bristol-Myers Squibb | Abilify® | Aripiprazole | Neuroscience/Mental Health | USD | 2,289 | 2,020 | -11.80% |
Bristol-Myers Squibb | Total: Neuroscience | | | USD | 2,289 | 2,020 | -11.80% |
Bristol-Myers Squibb | Orencia® | Abatacept | Immunology (Organ Transplant, Arthritis etc.) | USD | 1,444 | 1,652 | 14.40% |
Bristol-Myers Squibb | Total: Immunoscience | | | USD | 1,444 | 1,652 | 14.40% |
Bristol-Myers Squibb | Eliquis® | Apixaban | Anticoagulants | USD | 146 | 774 | 430.10% |
Bristol-Myers Squibb | Total: Cardiovascular | | | USD | 146 | 774 | 430.10% |
Bristol-Myers Squibb | Diabetes Alliance | divested to Astra Zeneca in Feb 2014 | | USD | 1,683 | 295 | -82.50% |
Bristol-Myers Squibb | Total: Other Mature Products | | | USD | 3,195 | 3,105 | -2.80% |
Bristol-Myers Squibb | Total Pharmaceuticals | | | USD | 16,385 | 15,879 | -3.10% |
AbbVie | Humira® | Adalimumab | Immunology (Organ Transplant, Arthritis etc.) | USD | 10,659 | 12,543 | 17.70% |
AbbVie | Androgel® | Testosterone | Hormonal Disorders | USD | 1,035 | 934 | -9.80% |
AbbVie | Kaletra® | Lopinavir/Ritonavir | Infectious Diseases (HIV, Hepatitis etc.) | USD | 962 | 870 | -9.60% |
AbbVie | Synagis® | Palivizumab | Respiratory Disorders | USD | 827 | 835 | 1.00% |
AbbVie | Lupron® | Leuprolide acetate | Oncology | USD | 785 | 778 | -0.90% |
AbbVie | Synthroid® | Levothyroxine Sodium | Hormonal Disorders | USD | 622 | 709 | 14.00% |
AbbVie | Sevoflurane® | Sevoflurane | Others | USD | 568 | 550 | -3.20% |
AbbVie | Creon® | Pancrelipase | Rare Disease | USD | 412 | 516 | 25.20% |
AbbVie | Dyslipidemia products | | Cardiovascular | USD | 1,076 | 328 | -69.50% |
AbbVie | Duodopa® | Carbidopa/Levodopa | Neuroscience/Mental Health | USD | 178 | 220 | 23.60% |
AbbVie | Viekira Pak® | Ombitasvir/Paritaprevir/Ritonavir | Infectious Diseases (HIV, Hepatitis etc.) | USD | - | 48 | |
AbbVie | Total: Other Mature Products | | | USD | 1,666 | 1,629 | -2.20% |
AbbVie | Total Pharmaceuticals | | | USD | 18,790 | 19,960 | 6.20% |
AstraZeneca | Crestor® | Rosuvastatin Calcium | Cardiovascular | USD | 5,622 | 5,512 | -2.00% |
AstraZeneca | Seloken®/Toprol-XL® | Metoprolol Hydrochloride | Antihypertensives | USD | 750 | 758 | 1.10% |
AstraZeneca | Onglyza/Kombiglyze XR/Komboglyze ® | Saxagliptin/Saxagliptin+Metoprolol Hydrochloride | Diabetes | USD | 378 | 820 | 116.90% |
AstraZeneca | Atacand® | Candesartan | Antihypertensives | USD | 611 | 501 | -18.00% |
AstraZeneca | Brilinta/Brilique® | Ticagrelor | Cardiovascular | USD | 283 | 476 | 68.20% |
AstraZeneca | Byetta® | Exenatide | Diabetes | USD | 206 | 327 | 58.70% |
AstraZeneca | Bydureon® | Exenatide | Diabetes | USD | 151 | 440 | 191.40% |
AstraZeneca | Plendil® | Felodipine | Antihypertensives | USD | 260 | 249 | -4.20% |
AstraZeneca | Tenormin® | Atenolol | Antihypertensives | USD | 197 | 161 | -18.30% |
AstraZeneca | Other Products | | | USD | 372 | 558 | 50.00% |
AstraZeneca | Total: Cardiovascular and Metabolic Diseases | | | USD | 8,830 | 9,802 | 11.00% |
AstraZeneca | Zoladex® | Goserelin Acetate | Oncology | USD | 996 | 924 | -7.20% |
AstraZeneca | Faslodex® | Fulvestrant | Oncology | USD | 681 | 720 | 5.70% |
AstraZeneca | Iressa® | Gefitinib | Oncology | USD | 647 | 623 | -3.70% |
AstraZeneca | Arimidex® | Anastrozole | Oncology | USD | 351 | 298 | -15.10% |
AstraZeneca | Casodex® | Bicalutamide | Oncology | USD | 376 | 320 | -14.90% |
AstraZeneca | Other Products | | | USD | 142 | 142 | 0.00% |
AstraZeneca | Total: Oncology | | | USD | 3,193 | 3,027 | -5.20% |
AstraZeneca | Symbicort® | Budesonide and Formoterol | Respiratory Disorders | USD | 3,483 | 3,801 | 9.10% |
AstraZeneca | Pulmicort® | Budesonide | Respiratory Disorders | USD | 867 | 946 | 9.10% |
AstraZeneca | Other Products | | | USD | 327 | 316 | -3.40% |
AstraZeneca | Total: Respiratory, Inflammation and Autoimmunity | | | USD | 4,677 | 5,063 | 8.30% |
AstraZeneca | Synagis® | Palivizumab | Respiratory Disorders | USD | 1,060 | 900 | -15.10% |
AstraZeneca | Merrem/Meronem® | Meropenem | Neuroscience and Mental Health | USD | 293 | 253 | -13.70% |
AstraZeneca | FluMist/Fluenz® | Influenza Vaccine Live, Intranasal | Infectious Diseases (HIV, Hepatitis etc.) | USD | 245 | 295 | 20.40% |
AstraZeneca | Other Products | | | USD | 89 | 78 | -12.40% |
AstraZeneca | Total: Infection | | | USD | 1,687 | 1,526 | -9.50% |
AstraZeneca | Seroquel XR® | Quetiapine Fumarate | Neuroscience/Mental Health | USD | 1,337 | 1,224 | -8.50% |
AstraZeneca | Seroquel IR® | Quetiapine Fumarate | Neuroscience/Mental Health | USD | 345 | 178 | -48.40% |
AstraZeneca | Local Anaesthetics | | | USD | 510 | 488 | -4.30% |
AstraZeneca | Vimovo® | Naproxen + Esomeprazole Magnesium | Bone Health | USD | 91 | 96 | 5.50% |
AstraZeneca | Other Products | | | USD | 452 | 420 | -7.10% |
AstraZeneca | Total: Neuroscience | | | USD | 2,735 | 2,406 | -12.00% |
AstraZeneca | Nexium | Esomeprazole Magnesium | Gastrointestinal Disorders | USD | 3,872 | 3,655 | -5.60% |
AstraZeneca | Losec/Prilosec | Omeprazole | Gastrointestinal Disorders | USD | 486 | 422 | -13.20% |
AstraZeneca | Other Products | | | USD | 231 | 194 | -16.00% |
AstraZeneca | Total: Gastrointestinal | | | USD | 4,589 | 4,271 | -6.90% |
AstraZeneca | Contribution of Other Products | | | USD | 1,613 | 1,708 | 5.90% |
AstraZeneca | Total Pharmaceuticals | | | USD | 25,711 | 26,095 | 1.50% |
Bayer | XareltoTM | Rivaroxaban | Anticoagulants | Euro | 949 | 1,679 | 76.90% |
Bayer | KogenateTM | Antihemophilic Factor (Recombinant) | Rare Disease | Euro | 1,202 | 1,109 | -7.70% |
Bayer | BetaferonTM/BetaseronTM | Interferon Beta-1b | Neuroscience/Mental Health | Euro | 1,038 | 819 | -21.10% |
Bayer | MirenaTM product family | Levonorgestrel | Sexual Health | Euro | 719 | 819 | 13.90% |
Bayer | NexavarTM | Sorafenib | Oncology | Euro | 771 | 773 | 0.30% |
Bayer | YAZTM/YasimTM/YasminelleTM | Drospirenone and Ethinyl Estradiol | Sexual Health | Euro | 853 | 768 | -10.00% |
Bayer | EyleaTM | Aflibercept | Diabetes | Euro | 333 | 759 | 127.90% |
Bayer | AdalatTM | Nifedipine | Antihypertensives | Euro | 603 | 588 | -2.50% |
Bayer | AspirinTM Cardio | Acetylsalicylic Acid | Cardiovascular | Euro | 452 | 486 | 7.50% |
Bayer | GlucobayTM | Acarbose | Diabetes | Euro | 423 | 443 | 4.70% |
Bayer | AvaloxTM/AveloxTM | Moxifloxacin Hydrochloride | Anti-bacterial | Euro | 426 | 381 | -10.60% |
Bayer | LevitraTM | Vardenafil Hydrochloride | Sexual Health | Euro | 290 | 245 | -15.50% |
Bayer | StivargaTM | Regorafenib | Oncology | Euro | 197 | 224 | 13.70% |
Bayer | CiproTM/CiproBayTM | Ciprofloxacin | Anti-bacterial | Euro | 197 | 191 | -3.00% |
Bayer | ZetiaTM | Ezetimibe | Cardiovascular | Euro | 172 | 168 | -2.30% |
Bayer | Other Products | | | Euro | 2,563 | 2,600 | 1.40% |
Bayer | Total Pharmaceuticals | | | Euro | 11,188 | 12,052 | 7.70% |
Bayer | Consumer Health | | | Euro | 7,736 | 7,923 | 2.40% |
Bayer | Total Healthcare | | | Euro | 18,924 | 19,975 | 5.60% |
Bayer | Crop Science | | | Euro | 8,819 | 9,494 | 7.70% |
Bayer | Material Science | | | Euro | 11,238 | 11,651 | 3.70% |
Bayer | Other Revenues | | | Euro | 1,176 | 1,119 | -4.80% |
Bayer | Group (incl. reconciliation) | | | Euro | 40,157 | 42,239 | 5.20% |
Amgen | Neulasta® | Pegfilgrastim | Blood Related Disorders | USD | 4,392 | 4,596 | 4.60% |
Amgen | Neupogen® | Filgrastim | Blood Related Disorders | USD | 1,398 | 1,159 | -17.10% |
Amgen | Enbrel® | Etanercept | Immunology (Organ Transplant, Arthritis etc.) | USD | 4,551 | 4,688 | 3.00% |
Amgen | Xgeva® | Denosumab | Oncology | USD | 1,019 | 1,221 | 19.80% |
Amgen | Prolia® | Denosumab | Bone Health | USD | 744 | 1,030 | 38.40% |
Amgen | Epogen® | Epoetin Alfa | Blood Related Disorders | USD | 1,953 | 2,031 | 4.00% |
Amgen | Aranesp® | Darbepoetin Alfa | Blood Related Disorders | USD | 1,911 | 1,930 | 1.00% |
Amgen | Sensipar®/Mimpara® | Cinacalcet | Hormonal Disorders | USD | 1,089 | 1,158 | 6.30% |
Amgen | Vectibix® | Panitumumab | Oncology | USD | 389 | 505 | 29.80% |
Amgen | Nplate® | Romiplostim | Immunology (Organ Transplant, Arthritis etc.) | USD | 427 | 469 | 9.80% |
Amgen | Kyprolis® | Carfilzomib | Oncology | USD | 73 | 331 | 353.40% |
Amgen | Blincyto™ | | | USD | - | 3 | |
Amgen | Total: Other Mature Products | | | USD | 246 | 206 | -16.30% |
Amgen | Total Pharmaceuticals | | | USD | 18,192 | 19,327 | 6.20% |
Amgen | Other revenues | | | USD | 484 | 736 | 52.10% |
Amgen | Total Revenues | | | USD | 18,676 | 20,063 | 7.40% |
Eli Lilly | Alimta® | Pemetrexed | Oncology | USD | 2,703 | 2,792 | 3.30% |
Eli Lilly | Humalog® | Insulin lispro | Diabetes | USD | 2,611 | 2,785 | 6.70% |
Eli Lilly | Cialis® | Tadalafil | Sexual Health | USD | 2,159 | 2,291 | 6.10% |
Eli Lilly | Cymbalta® | Duloxetine | Neuroscience/Mental Health | USD | 5,084 | 1,615 | -68.20% |
Eli Lilly | Humulin® | Insulin Isophane | Diabetes | USD | 1,316 | 1,400 | 6.40% |
Eli Lilly | Forteo® | Teriparatide | Bone Health | USD | 1,245 | 1,322 | 6.20% |
Eli Lilly | Zyprexa® | Olanzapine | Neuroscience/Mental Health | USD | 1,195 | 1,037 | -13.20% |
Eli Lilly | Strattera® | Atomoxetine | Neuroscience/Mental Health | USD | 709 | 739 | 4.10% |
Eli Lilly | Effient® | Prasugrel | Cardiovascular | USD | 509 | 522 | 45.20% |
Eli Lilly | Evista® | Raloxifene | Bone Health | USD | 1,050 | 420 | -60.00% |
Eli Lilly | Total: Other Mature Products | | | USD | 1,672 | 1,558 | -6.80% |
Eli Lilly | Animal Health | | | USD | 2,152 | 2,347 | 9.10% |
Eli Lilly | Total Pharmaceuticals | | | USD | 22,406 | 18,828 | -16.00% |
Eli Lilly | Other Revenues | | | USD | 708 | 788 | 11.40% |
Eli Lilly | Total Revenues | | | USD | 23,113 | 19,616 | -15.10% |
Teva | Copaxone® | Glatiramer | Neuroscience/Mental Health | USD | 4,328 | 4,237 | -2.10% |
Teva | Azilect® | Rasagiline | Neuroscience/Mental Health | USD | 371 | 428 | 15.40% |
Teva | Nuvigil® | Armodafinil | Sleep Disorders | USD | 320 | 388 | 21.30% |
Teva | Others | | | USD | 526 | 522 | -0.80% |
Teva | Total Neuroscience | | | USD | 5,545 | 5,575 | 0.50% |
Teva | Treanda® | Bendamustine | Oncology | USD | 709 | 767 | 8.20% |
Teva | Others | | | USD | 296 | 413 | 39.50% |
Teva | Total Oncology | | | USD | 1,005 | 1,180 | 17.40% |
Teva | ProAir® | Albuterol Sulfate | Respiratory Disorders | USD | 429 | 478 | 11.40% |
Teva | Qvar® | Beclomethasone | Respiratory Disorders | USD | 328 | 286 | -12.80% |
Teva | Others | | | USD | 207 | 193 | -6.80% |
Teva | Total Respiratory | | | USD | 964 | 957 | -0.70% |
Teva | Women's Health | | | USD | 510 | 504 | -1.20% |
Teva | Other Specialilty Medicines | | | USD | 364 | 344 | -5.50% |
Teva | Speciality Medicines | | | USD | 8,388 | 8,560 | 2.10% |
Teva | All Others | | | USD | 2,024 | 1,898 | -6.20% |
Teva | Generic Medicines | | | USD | 9,902 | 9,814 | -0.90% |
Teva | Total | | | USD | 20,314 | 20,272 | -0.20% |
GlaxoSmithKline | Avamys® / Veramys® | Fluticasone Furoate | Respiratory Disorders | GBP | 249 | 238 | -4.40% |
GlaxoSmithKline | Flixotide®/Flovent® | Fluticasone Propionate | Respiratory Disorders | GBP | 796 | 702 | -11.80% |
GlaxoSmithKline | Relvar®/Breo Ellipta® | Fluticasone Furoate | Respiratory Disorders | GBP | 8 | 67 | 737.50% |
GlaxoSmithKline | Seretide®/Advair® | Salmeterol | Respiratory Disorders | GBP | 5,274 | 4,229 | -19.80% |
GlaxoSmithKline | Ventolin® | Albuterol | Respiratory Disorders | GBP | 642 | 665 | 3.60% |
GlaxoSmithKline | Other | | | GBP | 320 | 280 | -12.50% |
GlaxoSmithKline | Total Respiratory | | | GBP | 7,289 | 6,181 | -15.20% |
GlaxoSmithKline | Arzerra® | Ofatumumab | Oncology | GBP | 75 | 54 | -28.00% |
GlaxoSmithKline | Mekinist® | Trametinib | Oncology | GBP | 10 | 68 | 580.00% |
GlaxoSmithKline | Promacta® | Eltrombopag | Oncology | GBP | 186 | 231 | 24.20% |
GlaxoSmithKline | Tafinlar® | Dabrafenib | Oncology | GBP | 16 | 135 | 743.80% |
GlaxoSmithKline | Tyverb®/Tykerb® | Lapatinib | Oncology | GBP | 207 | 171 | -17.40% |
GlaxoSmithKline | Votrient® | Pazopanib | Oncology | GBP | 331 | 410 | 23.90% |
GlaxoSmithKline | Other | | | GBP | 144 | 133 | -7.60% |
GlaxoSmithKline | Total Oncology | | | GBP | 969 | 1,202 | 24.00% |
GlaxoSmithKline | Avodart® | Dutasteride | Urology | GBP | 857 | 805 | -6.10% |
GlaxoSmithKline | Other | | | GBP | 216 | 160 | -25.90% |
GlaxoSmithKline | Total Cardiovascular,metabolic and urology | | | GBP | 1,073 | 965 | -10.10% |
GlaxoSmithKline | Benlysta® | Belimumab | Rare Disease | GBP | 146 | 173 | 18.50% |
GlaxoSmithKline | Other | | | GBP | 15 | 41 | 173.30% |
GlaxoSmithKline | Total Immunoinflammation | | | GBP | 161 | 214 | 32.90% |
GlaxoSmithKline | Dermatology | | | GBP | 631 | 481 | -23.80% |
GlaxoSmithKline | Augmentin® | Amoxicillin and Clavulanate Potassium | Anti-bacterial | GBP | 630 | 573 | -9.00% |
GlaxoSmithKline | Other anti-bacterials | | | GBP | 224 | 215 | -4.00% |
GlaxoSmithKline | Rare diseases | | | GBP | 495 | 417 | -15.80% |
GlaxoSmithKline | Other | | | GBP | 694 | 721 | 3.90% |
GlaxoSmithKline | Other pharmaceuticals | | | GBP | 2,674 | 2,407 | -10.00% |
GlaxoSmithKline | Boostrix® | Vaccine | Vaccine | GBP | 288 | 317 | 10.10% |
GlaxoSmithKline | Cervarix® | Vaccine | Vaccine | GBP | 172 | 118 | -31.40% |
GlaxoSmithKline | Fluarix®, FluLaval® | Vaccine | Vaccine | GBP | 251 | 215 | -14.30% |
GlaxoSmithKline | Hepatitis | Vaccine | | GBP | 629 | 558 | -11.30% |
GlaxoSmithKline | Infanrix®, Pediarix ® | Vaccine | Vaccine | GBP | 862 | 828 | -3.90% |
GlaxoSmithKline | Rotarix® | Vaccine | Vaccine | GBP | 375 | 376 | 0.30% |
GlaxoSmithKline | Synflorix® | Vaccine | Vaccine | GBP | 405 | 398 | -1.70% |
GlaxoSmithKline | Other | | | GBP | 438 | 382 | -12.80% |
GlaxoSmithKline | Vaccines | | | GBP | 3,420 | 3,192 | -6.70% |
GlaxoSmithKline | Innovative Pharmaceuticals | | | GBP | 12,166 | 10,969 | -9.80% |
GlaxoSmithKline | Total Innovative Pharmaceuticals and Vaccines | | | GBP | 15,586 | 14,161 | -9.10% |
GlaxoSmithKline | Combivir® | Lamivudine and zidovudine. | Infectious Diseases (HIV, Hepatitis etc.) | GBP | 116 | 59 | -49.10% |
GlaxoSmithKline | Epzicom®/Kivexa® | Abacavir and Lamivudine | Infectious Diseases (HIV, Hepatitis etc.) | GBP | 763 | 768 | 0.70% |
GlaxoSmithKline | Lexiva®/Agenerase® | Fosamprenavir | Infectious Diseases (HIV, Hepatitis etc.) | GBP | 113 | 87 | -23.00% |
GlaxoSmithKline | Selzentry® | Maraviroc | Infectious Diseases (HIV, Hepatitis etc.) | GBP | 143 | 136 | -4.90% |
GlaxoSmithKline | Tivicay® | Dolutegravir | Infectious Diseases (HIV, Hepatitis etc.) | GBP | 19 | 282 | 1384.20% |
GlaxoSmithKline | Trizivir® | Abacavir, Lamivudine, and Zidovudine | Infectious Diseases (HIV, Hepatitis etc.) | GBP | 97 | 36 | -62.90% |
GlaxoSmithKline | Other | | | GBP | 135 | 130 | -3.70% |
GlaxoSmithKline | ViiV Healthcare (HIV) | | | GBP | 1,386 | 1,498 | 8.10% |
GlaxoSmithKline | Coreg® | Carvedilol | Antihypertensives | GBP | 131 | 124 | -5.30% |
GlaxoSmithKline | Hepsera® | Adefovir | Infectious Diseases (HIV, Hepatitis etc.) | GBP | 96 | 85 | -11.50% |
GlaxoSmithKline | Imigran®/Imitrex® | Sumatriptan Succinate | Neuroscience/Mental Health | GBP | 188 | 172 | -8.50% |
GlaxoSmithKline | Lamictal® | Lamotrigine | Neuroscience/Mental Health | GBP | 557 | 531 | -4.70% |
GlaxoSmithKline | Lovaza® | Omega-3 Polyunsaturated Fatty Acids | Cardiovascular | GBP | 584 | 240 | -58.90% |
GlaxoSmithKline | Requip® | Ropinirole | Neuroscience/Mental Health | GBP | 125 | 109 | -12.80% |
GlaxoSmithKline | Serevent® | Salmeterol | Respiratory Disorders | GBP | 129 | 108 | -16.30% |
GlaxoSmithKline | Seroxat®/Paxil® | Paroxetine Hydrochloride Hemihydrate | Neuroscience/Mental Health | GBP | 285 | 210 | -26.30% |
GlaxoSmithKline | Valtrex® | Valacyclovir | Infectious Diseases (HIV, Hepatitis etc.) | GBP | 224 | 154 | -31.30% |
GlaxoSmithKline | Zeffix® | Lamivudine | Infectious Diseases (HIV, Hepatitis etc.) | GBP | 182 | 166 | -8.80% |
GlaxoSmithKline | Other | | | GBP | 1,373 | 1,112 | -19.00% |
GlaxoSmithKline | Established Products | | | GBP | 3,874 | 3,011 | -22.30% |
GlaxoSmithKline | Total | | | GBP | 20,846 | 18,670 | -10.40% |
GlaxoSmithKline | Consumer Healthcare Turnover | | | GBP | 4,756 | 4,336 | -8.80% |
GlaxoSmithKline | Total Sales | | | GBP | 25,602 | 23,006 | -10.10% |
Novartis | Onbrez Breezhaler®/Arcapta Neohaler® | Indacaterol Maleate | Respiratory Disorders | USD | 192 | 220 | 14.60% |
Novartis | Seebri Breezhaler® | Glycopyrronium Bromide | Respiratory Disorders | USD | 58 | 146 | 151.70% |
Novartis | Ultibro Breezhaler® | Indacaterol / Glycopyrronium Bromide | Respiratory Disorders | USD | 6 | 118 | 1866.70% |
Novartis | Subtotal COPD Portfolio | | | USD | 256 | 484 | 89.10% |
Novartis | Galvus® | Vildagliptin | Diabetes | USD | 1,200 | 1,224 | 2.00% |
Novartis | Xolair® | Omalizumab | Respiratory Disorders | USD | 613 | 777 | 26.80% |
Novartis | TOBI® | Tobramycin | Respiratory Disorders | USD | 387 | 281 | -27.40% |
Novartis | Other | | | USD | 40 | 46 | 15.00% |
Novartis | Total strategic franchise products | | | USD | 2,496 | 2,812 | 12.70% |
Novartis | Diovan® | Hydrochlorothiazide and Valsartan | Antihypertensives | USD | 3,524 | 2,345 | -33.50% |
Novartis | Exforge® | Amlodipine and Valsartan. | Antihypertensives | USD | 1,456 | 1,396 | -4.10% |
Novartis | Tekturna®/Rasilez® | Aliskiren | Antihypertensives | USD | 290 | 207 | -28.60% |
Novartis | Other | | | USD | 1,312 | 1,201 | -8.50% |
Novartis | Total Established medicines | | | USD | 6,582 | 5,149 | -21.80% |
Novartis | Total Primary Care products | | | USD | 9,078 | 7,961 | -12.30% |
Novartis | Gleevec®/Glivec® | Imatinib | Oncology | USD | 4,693 | 4,746 | 1.10% |
Novartis | Tasigna® | Nilotinib | Oncology | USD | 1,266 | 1,529 | 20.80% |
Novartis | Subtotal Bcr-Abl franchise | | | USD | 5,959 | 6,275 | 5.30% |
Novartis | Sandostatin® | Octreotide | Oncology | USD | 1,589 | 1,650 | 3.80% |
Novartis | Afinitor®/Votubia® | Everolimus | Oncology | USD | 1,309 | 1,575 | 20.30% |
Novartis | Exjade® | Deferasirox | Blood Related Disorders | USD | 893 | 926 | 3.70% |
Novartis | Femara® | Letrozole | Oncology | USD | 384 | 380 | -1.00% |
Novartis | Jakavi® | Ruxolitinib | Oncology | USD | 163 | 279 | 71.20% |
Novartis | Zometa® | Zoledronic Acid | Oncology | USD | 600 | 264 | -56.00% |
Novartis | Proleukin® | Aldesleukin | Oncology | USD | 91 | 74 | -18.70% |
Novartis | Zykadia® | Ceritinib | Oncology | USD | - | 31 | |
Novartis | Other | | | USD | 228 | 249 | 9.20% |
Novartis | Total Oncology products | | | USD | 11,216 | 11,703 | 4.30% |
Novartis | Gilenya® | Fingolimod | Neuroscience/Mental Health | USD | 1,934 | 2,477 | 28.10% |
Novartis | Exelon®/Exelon Patch® | Rivastigmine | Neuroscience/Mental Health | USD | 1,032 | 1,009 | -2.20% |
Novartis | Comtan®/Stalevo® | Entacapone | Neuroscience/Mental Health | USD | 401 | 371 | -7.50% |
Novartis | Extavia® | Interferon Beta-1b | Neuroscience/Mental Health | USD | 159 | 177 | 11.30% |
Novartis | other | | | USD | 78 | 66 | -15.40% |
Novartis | Total strategic franchise products | | | USD | 3,604 | 4,100 | 13.80% |
Novartis | Established Medicines | | | USD | 444 | 409 | -7.90% |
Novartis | Total Neuroscience Products | | | USD | 4,048 | 4,509 | 11.40% |
Novartis | Lucentis® | Ranibizumab | Opthamology | USD | 2,383 | 2,441 | 2.40% |
Novartis | Other | | | USD | 61 | 63 | 3.30% |
Novartis | Total Opthalmics Products | | | USD | 2,444 | 2,504 | 2.50% |
Novartis | Neoral®/Sandimmun® | Cyclosporine | Immunology (Organ Transplant, Arthritis etc.) | USD | 750 | 684 | -8.80% |
Novartis | Myfortic® | Mycophenolic Acid | Immunology (Organ Transplant, Arthritis etc.) | USD | 637 | 543 | -14.80% |
Novartis | Zortress®/Certican® | Everolimus | Immunology (Organ Transplant, Arthritis etc.) | USD | 249 | 327 | 31.30% |
Novartis | Ilaris® | Canakinumab | Rare Disease | USD | 119 | 199 | 67.20% |
Novartis | Other | | | USD | 169 | 173 | 2.40% |
Novartis | Total strategic franchise products | | | USD | 1,924 | 1,926 | 0.10% |
Novartis | Everolimus stent drug | Everolimus | Immunology (Organ Transplant, Arthritis etc.) | USD | 247 | 205 | -17.00% |
Novartis | Established Medicines | | | USD | 1,112 | 981 | -11.80% |
Novartis | Total IHC Products | | | USD | 3,283 | 3,112 | -5.20% |
Novartis | Voltaren® | Diclofenac | Others | USD | 675 | 632 | -6.40% |
Novartis | Ritalin®/Focalin® | Methylphenidate | Neuroscience/Mental Health | USD | 594 | 492 | -17.20% |
Novartis | Tegretol® | Carbamazepine | Neuroscience/Mental Health | USD | 342 | 346 | 1.20% |
Novartis | Trileptal® | Oxcarbazepine | Neuroscience/Mental Health | USD | 257 | 265 | 3.10% |
Novartis | Foradil® | Formoterol | Respiratory Disorders | USD | 205 | 175 | -14.60% |
Novartis | Other | | | USD | 72 | 92 | 27.80% |
Novartis | Total Additional Products | | | USD | 2,145 | 2,002 | -6.70% |
Novartis | Total strategic franchise products | | | USD | 21,684 | 23,045 | 6.30% |
Novartis | Total Established medicines and additional products | | | USD | 10,530 | 8,746 | -16.90% |
Novartis | Total Division net Sales | | | USD | 32,214 | 31,791 | -1.30% |
Novartis | Net Sales by Alcon | | | USD | 10,496 | 10,827 | 3.20% |
Novartis | Net Sales by Sandoz | | | USD | 9,159 | 9,562 | 4.40% |
Novartis | Total Sales by Continuing operation | | | USD | 51,869 | 52,180 | 0.60% |
Novartis | Total Sales by discontinuing operation | | | USD | 6,051 | 5,816 | -3.90% |
Novartis | Total Group Net Sales | | | USD | 57,920 | 57,996 | 0.10% |
Merck & Co | Zetia® | Ezetimibe | Cardiovascular | USD | 2,658 | 2,650 | -0.30% |
Merck & Co | Vytorin® | Ezetimibe and Simvastatin | Cardiovascular | USD | 1,643 | 1,516 | -7.70% |
Merck & Co | Total Cardiovascular | | | USD | 4,301 | 4,166 | -3.10% |
Merck & Co | Januvia® | Sitagliptin | Diabetes | USD | 4,004 | 3,931 | -1.80% |
Merck & Co | Janumet® | Metformin and Sitagliptin | Diabetes | USD | 1,829 | 2,071 | 13.20% |
Merck & Co | Total Diabetes | | | USD | 5,833 | 6,002 | 2.90% |
Merck & Co | NuvaRing® | Ethinyl Estradiol And Etonogestrel | Sexual Health | USD | 686 | 723 | 5.40% |
Merck & Co | Implanin®/Nexplanon® | Etonogestrel | Sexual Health | USD | 403 | 502 | 24.60% |
Merck & Co | Dulera® | Formoterol and Mometasone | Respiratory Disorders | USD | 324 | 460 | 42.00% |
Merck & Co | Follistim AQ® | Follicle Stimulating Hormone | Sexual Health | USD | 481 | 412 | -14.30% |
Merck & Co | General Medicine and Women's Health | | | USD | 1,894 | 2,097 | 10.70% |
Merck & Co | PegIntron® | Peginterferon alfa-2b | Infectious Diseases (HIV, Hepatitis etc.) | USD | 496 | 381 | -23.20% |
Merck & Co | Victrelis® | Boceprevir | Infectious Diseases (HIV, Hepatitis etc.) | USD | 428 | 153 | -64.30% |
Merck & Co | Total Hepatitis | | | USD | 924 | 534 | -42.20% |
Merck & Co | Isentress® | Raltegravir | Infectious Diseases (HIV, Hepatitis etc.) | USD | 1,643 | 1,673 | 1.80% |
Merck & Co | Total HIV | | | USD | 1,643 | 1,673 | 1.80% |
Merck & Co | Cancidas® | Caspofungin | Anti-fungal | USD | 660 | 681 | 3.20% |
Merck & Co | Invanz® | Ertapenem | Anti-bacterial | USD | 488 | 529 | 8.40% |
Merck & Co | Noxafil® | Posaconazole | Anti-fungal | USD | 309 | 402 | 30.10% |
Merck & Co | Bridion® | Sugammadex | Neuroscience/Mental Health | USD | 288 | 340 | 18.10% |
Merck & Co | Primaxin® | Imipenem and Cilastatin | Anti-bacterial | USD | 335 | 329 | -1.80% |
Merck & Co | Total Acute Care | | | USD | 2,080 | 2,281 | 9.70% |
Merck & Co | Remicade® | Infliximab | Immunology (Organ Transplant, Arthritis etc.) | USD | 2,271 | 2,372 | 4.40% |
Merck & Co | Simponi® | Golimumab | Immunology (Organ Transplant, Arthritis etc.) | USD | 500 | 689 | 37.80% |
Merck & Co | Total Immunology | | | USD | 2,771 | 3,061 | 10.50% |
Merck & Co | Cosopt®/Trusopt® | Dorzolamide and Timolol | Opthamology | USD | 416 | 257 | -38.20% |
Merck & Co | Total others | | | USD | 416 | 257 | -38.20% |
Merck & Co | Emend® | Aprepitant | Others | USD | 507 | 553 | 9.10% |
Merck & Co | Temodar® | Temozolomide | Oncology | USD | 708 | 350 | -50.60% |
Merck & Co | Keytruda® | Pembrolizumab | Oncology | USD | - | 55 | |
Merck & Co | Total Oncology | | | USD | 1,215 | 958 | -21.20% |
Merck & Co | Nasonex® | Mometasone Furoate | Respiratory Disorders | USD | 1,335 | 1,099 | -17.70% |
Merck & Co | Singulair® | Montelukast Sodium | Respiratory Disorders | USD | 1,196 | 1,092 | -8.70% |
Merck & Co | Clarinex® | Desloratadine | Immunology (Organ Transplant, Arthritis etc.) | USD | 235 | 232 | -1.30% |
Merck & Co | Total Respiratory | | | USD | 2,766 | 2,423 | -12.40% |
Merck & Co | Cozaar®/Hyzaar® | Losartan and Hydrochlorothiazide | Antihypertensives | USD | 1,006 | 806 | -19.90% |
Merck & Co | Arcoxia® | Etoricoxib | Immunology (Organ Transplant, Arthritis etc.) | USD | 484 | 519 | 7.20% |
Merck & Co | Fosamax® | Alendronate | Bone Health | USD | 560 | 470 | -16.10% |
Merck & Co | Propecia® | Finasteride | Others | USD | 283 | 264 | -6.70% |
Merck & Co | Zocor® | Simvastatin | Antihypertensives | USD | 301 | 258 | -14.30% |
Merck & Co | Remeron® | Mirtazapine | Neuroscience/Mental Health | USD | 206 | 193 | -6.30% |
Merck & Co | Total Other | | | USD | 2,840 | 2,510 | -11.60% |
Merck & Co | Gardasil® | Vaccine | Oncology | USD | 1,831 | 1,738 | -5.10% |
Merck & Co | ProQuad®/M-M-R II® / Varivax® | | Vaccine | USD | 1,306 | 1,394 | 6.70% |
Merck & Co | Zostavax® | | Infectious Diseases (HIV, Hepatitis etc.) | USD | 758 | 765 | 0.90% |
Merck & Co | Pneumovax 23® | | Vaccine | USD | 653 | 746 | 14.20% |
Merck & Co | RotaTeq® | | Vaccine | USD | 636 | 659 | 3.60% |
Merck & Co | Total Vaccine | | | USD | 5,184 | 5,302 | 2.30% |
Merck & Co | Other Pharmaceutical | | | USD | 5,570 | 4,778 | -14.20% |
Merck & Co | Total Pharmaceutical Segment Sales | | | USD | 37,437 | 36,042 | -3.70% |
Merck & Co | Other Segment Sales | | | USD | 6,325 | 5,585 | -11.70% |
Merck & Co | Total Segment sales | | | USD | 43,762 | 41,627 | -4.90% |
Merck & Co | Others | | | USD | 271 | 610 | 125.10% |
Merck & Co | Total | | | USD | 44,033 | 42,237 | -4.10% |
Roche | Avastin® | Bevacizumab | Oncology | CHF | 6,254 | 6,417 | 2.60% |
Roche | Herceptin® | Trastuzumab | Oncology | CHF | 6,079 | 6,275 | 3.20% |
Roche | MabThera®/Rituxan® | Rituximab | Oncology | CHF | 5,760 | 5,603 | -2.70% |
Roche | Tarceva® | Erlotinib | Oncology | CHF | 1,339 | 1,292 | -3.50% |
Roche | Perjeta® | Pertuzumab | Oncology | CHF | 326 | 918 | 181.60% |
Roche | Xeloda® | Capecitabine | Oncology | CHF | 1,509 | 776 | -48.60% |
Roche | Kadcyla® | Trastuzumab Emtansine | Oncology | CHF | 234 | 536 | 129.10% |
Roche | Zelboraf® | Vemurafenib | Oncology | CHF | 354 | 301 | -15.00% |
Roche | Others | | | CHF | 698 | 679 | -2.70% |
Roche | Total: Oncology | | | CHF | 22,553 | 22,797 | 1.10% |
Roche | MabThera®/Rituxan® | Rituximab | Oncology | CHF | 1,191 | 1,297 | 8.90% |
Roche | Actemra®/RoActemra® | Tocilizumab | Immunology (Organ Transplant, Arthritis etc.) | CHF | 1,037 | 1,224 | 18.00% |
Roche | Xolair® | Omalizumab | Respiratory Disorders | CHF | 790 | 975 | 23.40% |
Roche | CellCept® | Mycophenolate Mofetil | Immunology (Organ Transplant, Arthritis etc.) | CHF | 874 | 811 | -7.20% |
Roche | Pulmozyme® | Dornase Alfa | Rare Disease | CHF | 572 | 597 | 4.40% |
Roche | Others | | | CHF | 164 | 183 | 11.60% |
Roche | Total: Immunology | | | CHF | 4,628 | 5,087 | 9.90% |
Roche | Pegasys® | Peginterferon Alfa-2a | Infectious Diseases (HIV, Hepatitis etc.) | CHF | 1,312 | 1,015 | -22.60% |
Roche | Tamiflu® | Oseltamivir Phosphate | Infectious Diseases (HIV, Hepatitis etc.) | CHF | 635 | 959 | 51.00% |
Roche | Valcyte®/Cymevene® | Ganciclovir and Valganciclovir | Immunology (Organ Transplant, Arthritis etc.) | CHF | 693 | 726 | 4.80% |
Roche | Rocephin® | Ceftriaxone | Neuroscience/Mental Health | CHF | 268 | 283 | 5.60% |
Roche | Others | | | CHF | 272 | 211 | -22.40% |
Roche | Total: Infectious Diseases | | | CHF | 3,180 | 3,194 | 0.40% |
Roche | Lucentis® | Ranibizumab | Opthamology | CHF | 1,689 | 1,701 | 0.70% |
Roche | Total: Opthalmology | | | CHF | 1,689 | 1,701 | 0.70% |
Roche | Madopar® | Levodopa and Benserazide | Neuroscience/Mental Health | CHF | 313 | 292 | -6.70% |
Roche | Others | | | CHF | 497 | 434 | -12.70% |
Roche | Total: Neuroscience | | | CHF | 810 | 726 | -10.40% |
Roche | Activase®/TNKase® | Tenecteplase | Cardiovascular | CHF | 683 | 747 | 9.40% |
Roche | NeoRecormon®/Epogin® | Epoetin Beta and Epoetin Alfa | Blood Related Disorders | CHF | 520 | 460 | -11.50% |
Roche | Mircera® | Methoxy Polyethylene Glycol and Epoetin Beta | Blood Related Disorders | CHF | 425 | 417 | -1.90% |
Roche | Nutropin® | Somatropin | Hormonal Disorders | CHF | 274 | 214 | -21.90% |
Roche | Others | | | CHF | 1,542 | 1,353 | -12.30% |
Roche | Total Other therapeutic areas | | | CHF | 3,444 | 3,191 | -7.30% |
Roche | Total Sales | | | CHF | 36,304 | 36,696 | 1.10% |
Roche | Royalties and Other Operating Income | | | CHF | 1,702 | 2,273 | 33.50% |
Roche | Total | | | CHF | 38,006 | 38,969 | 2.50% |
Roche | Diagnostic Division | | | CHF | 10,476 | 10,766 | 2.80% |
Roche | Royalties and Other Operating Income | | | CHF | 130 | 131 | 0.80% |
Roche | Total Group Sale | | | CHF | 48,612 | 49,866 | 2.60% |
Gilead Sciences | Sovaldi® | Sofosbuvir | Infectious Diseases (HIV, Hepatitis etc.) | USD | 139 | 10,283 | 7297.80% |
Gilead Sciences | Atripla® | Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate | Infectious Diseases (HIV, Hepatitis etc.) | USD | 3,648 | 3,470 | -4.90% |
Gilead Sciences | Truvada® | Emtricitabine, and Tenofovir Disoproxil Fumarate | Infectious Diseases (HIV, Hepatitis etc.) | USD | 3,136 | 3,340 | 6.50% |
Gilead Sciences | Harvoni® | Ledipasvir and Sofosbuvir | Infectious Diseases (HIV, Hepatitis etc.) | USD | - | 2,127 | |
Gilead Sciences | Complera®/Eviplera® | Rilpivirine, Emtricitabine, and Tenofovir Disoproxil Fumarate | Infectious Diseases (HIV, Hepatitis etc.) | USD | 810 | 1,228 | 51.60% |
Gilead Sciences | Stribild® | Cobicistat, Elvitegravir, Emtricitabine and Tenofovir Disoproxil Fumarate | Infectious Diseases (HIV, Hepatitis etc.) | USD | 539 | 1,197 | 122.10% |
Gilead Sciences | Viread® | Tenofovir Disoproxil Fumarate | Infectious Diseases (HIV, Hepatitis etc.) | USD | 959 | 1,058 | 10.30% |
Gilead Sciences | Other antiviral | | | USD | 111 | 88 | -20.70% |
Gilead Sciences | Total antiviral products | | | USD | 9,342 | 22,791 | 144.00% |
Gilead Sciences | Letairis® | Ambrisentan | Antihypertensives | USD | 520 | 595 | 14.40% |
Gilead Sciences | Ranexa® | Ranolazine | Cardiovascular | USD | 449 | 510 | 13.60% |
Gilead Sciences | AmBisome® | Amphotericin B | Infectious Diseases (HIV, Hepatitis etc.) | USD | 352 | 388 | 10.20% |
Gilead Sciences | Zydelig® | Idelalisib | Oncology | USD | - | 23 | |
Gilead Sciences | others | | | USD | 141 | 167 | 18.40% |
Gilead Sciences | Total Other Products | | | USD | 1,462 | 1,683 | 15.10% |
Gilead Sciences | Total Product Sales | | | USD | 10,804 | 24,474 | 126.50% |
Gilead Sciences | Royalty Contract and Other Revenues | | | USD | 398 | 416 | 4.50% |
Gilead Sciences | Total Revenues | | | USD | 11,202 | 24,890 | 122.20% |
Pfizer Inc. | Lyrica® | Pregabalin | Neuroscience/Mental Health | USD | 4,595 | 5,168 | 12.50% |
Pfizer Inc. | Prevnar Family | Pneumococcal 7-Valent Conjugate | Anti-bacterial | USD | 3,974 | 4,464 | 12.30% |
Pfizer Inc. | Enbrel® | Etanercept | Immunology (Organ Transplant, Arthritis etc.) | USD | 3,774 | 3,850 | 2.00% |
Pfizer Inc. | Celebrex® | Celecoxib | Bone Health | USD | 2,918 | 2,699 | -7.50% |
Pfizer Inc. | Lipitor® | Atorvastatin Calcium | Cardiovascular | USD | 2,315 | 2,062 | -10.90% |
Pfizer Inc. | Viagra® | Sildenafil Citrate | Sexual Health | USD | 1,881 | 1,685 | -10.40% |
Pfizer Inc. | Zyvox® | Linezolid | Anti-bacterial | USD | 1,353 | 1,351 | -0.10% |
Pfizer Inc. | Sutent® | Sunitinib Malate | Oncology | USD | 1,204 | 1,175 | -2.40% |
Pfizer Inc. | Norvase® | Amlodipine | Antihypertensives | USD | 1,229 | 1,112 | -9.50% |
Pfizer Inc. | Premarin Family | Conjugated Estrogens | Sexual Health | USD | 1,092 | 1,076 | -1.50% |
Pfizer Inc. | BeneFIX® | Coagulation Factor IX | Rare Disease | USD | 832 | 856 | 2.90% |
Pfizer Inc. | Vfend® | Voriconazole | Anti-fungal | USD | 775 | 755 | -2.60% |
Pfizer Inc. | Pristiq® | Desvenlafaxine | Neuroscience/Mental Health | USD | 698 | 738 | 5.70% |
Pfizer Inc. | Genotropin® | Somatropin | Rare Disease | USD | 772 | 723 | -6.30% |
Pfizer Inc. | Chantix®/Champix® | Varenicline | Neuroscience/Mental Health | USD | 648 | 646 | -0.30% |
Pfizer Inc. | Refacto AF®/Xyntha® | Antihemophilic Factor (Recombinant) | Rare Disease | USD | 602 | 630 | 4.70% |
Pfizer Inc. | Xalatan®/Xalacom® | Latanoprost | Opthamology | USD | 589 | 495 | -16.00% |
Pfizer Inc. | Medrol® | Methylprednisolone | Immunology (Organ Transplant, Arthritis etc.) | USD | 464 | 443 | -4.50% |
Pfizer Inc. | Xalkori® | Crizotinib | Oncology | USD | 282 | 437 | 55.00% |
Pfizer Inc. | Zoloft® | Sertraline | Neuroscience/Mental Health | USD | 469 | 424 | -9.60% |
Pfizer Inc. | Inlyta® | Axitinib | Oncology | USD | 319 | 411 | 28.80% |
Pfizer Inc. | Relpax® | Eletriptan Hydrobromide | Neuroscience/Mental Health | USD | 359 | 381 | 6.10% |
Pfizer Inc. | Fragmin® | Dalteparin | Anticoagulants | USD | 359 | 364 | 1.40% |
Pfizer Inc. | Sulperazon® | Cefoperazone and Sulbactam | Urology | USD | 309 | 355 | 14.90% |
Pfizer Inc. | Effexor® | Venlafaxine | Neuroscience/Mental Health | USD | 440 | 344 | -21.80% |
Pfizer Inc. | Rapamune® | Sirolimus | Immunology (Organ Transplant, Arthritis etc.) | USD | 350 | 339 | -3.10% |
Pfizer Inc. | Tygacil® | Tigecycline | Anti-bacterial | USD | 358 | 323 | -9.80% |
Pfizer Inc. | Zithromax®/Zmax® | Azithromycin | Anti-bacterial | USD | 387 | 313 | -19.10% |
Pfizer Inc. | Xeljianz® | Tofacitinib citrate | Immunology (Organ Transplant, Arthritis etc.) | USD | 114 | 308 | 170.20% |
Pfizer Inc. | Zosyn®/Tazocin® | Piperacillin and Tazobactam | Infectious Diseases (HIV, Hepatitis etc.) | USD | 395 | 303 | -23.30% |
Pfizer Inc. | EpiPen® | Epinephrine | Immunology (Organ Transplant, Arthritis etc.) | USD | 273 | 294 | 7.70% |
Pfizer Inc. | Toviaz® | Fesoterodine fumarate | Urology | USD | 236 | 289 | 22.50% |
Pfizer Inc. | Revatio® | Sildenafil | Antihypertensives | USD | 307 | 276 | -10.10% |
Pfizer Inc. | Cardura® | Doxazosin mesylate | Antihypertensives | USD | 296 | 263 | -11.10% |
Pfizer Inc. | Xanax®/ Xanax XR® | Alprazolam | Neuroscience/Mental Health | USD | 276 | 252 | -8.70% |
Pfizer Inc. | Inspra® | Eplerenone | Cardiovascular | USD | 233 | 234 | 0.40% |
Pfizer Inc. | Somavert® | Pegvisomant | Hormonal Disorders | USD | 217 | 229 | 5.50% |
Pfizer Inc. | BMP2 | Bone Morphogenetic Proteins | Bone Health | USD | 209 | 228 | 9.10% |
Pfizer Inc. | Diflucan® | Fluconazole | Anti-fungal | USD | 242 | 220 | -9.10% |
Pfizer Inc. | Neurontin® | Neurontin | Neuroscience/Mental Health | USD | 216 | 211 | -2.30% |
Pfizer Inc. | Unasyn® | Ampicillin-sulbactam | Anti-bacterial | USD | 212 | 207 | -2.40% |
Pfizer Inc. | Detrol®/Detrol LA® | Tolterodine tartrate | Urology | USD | 562 | 201 | -64.20% |
Pfizer Inc. | Depo-Provera® | Medroxyprogesterone | Sexual Health | USD | 191 | 201 | 5.20% |
Pfizer Inc. | Protonix®/Pantoprazole | Pantoprazole Sodium | Gastrointestinal Disorders | USD | 185 | 198 | 7.00% |
Pfizer Inc. | Dalacin®/Cleocin® | Clindamycin Palmitate Hydrochloride | Anti-bacterial | USD | 200 | 184 | -8.00% |
Pfizer Inc. | Caduet® | Amlodipine and Atorvastatin | Antihypertensives | USD | 223 | 182 | -18.40% |
Pfizer Inc. | Total Sales (Region) | | | USD | 37,934 | 37,899 | -0.10% |
Pfizer Inc. | Alliance Revenues | | | USD | 2,628 | 1,222 | -53.50% |
Pfizer Inc. | All other Bio-Pharmaceuticals | | | USD | 7,316 | 11,503 | 57.20% |
Pfizer Inc. | Total Sales | | | USD | 47,878 | 45,712 | -4.50% |
Pfizer Inc. | Consumer HealthCare | | | USD | 3,342 | 3,446 | 3.10% |
Pfizer Inc. | Other | | | USD | 364 | 451 | 23.90% |
Pfizer Inc. | Total Final | | | USD | 51,584 | 49,609 | -3.80% |
Mylan | EpiPen® | Epinephrine | Immunology (Organ Transplant, Arthritis etc.) | Euro | 1000 | | |
Mylan | Other Products | | | Euro | 6646.5 | 6856.6 | -3% |
Mylan | Other Revenues | | | Euro | 73.1 | 52.5 | 39% |
Mylan | Total Revenues | | | Euro | 7719.6 | 6909.1 | 12% |
Boehringer Ingelheim | Spiriva® | Tiotropium Bromide | Respiratory Disorders | Euro | 3,237 | 3,552 | -9% |
Boehringer Ingelheim | Pradaxa® | Dabigatran Etexilate Mesylate | Cardiovascular | Euro | 1,198 | 1,206 | -1% |
Boehringer Ingelheim | Micardis® | Telmisartan | Antihypertensives | Euro | 1,088 | 1,373 | -21% |
Boehringer Ingelheim | Combivent® | Ipratropium Bromide and Albuterol | Respiratory Disorders | Euro | 563 | 711 | -21% |
Boehringer Ingelheim | Other Products | | | Euro | 4,015 | 4,049 | -1% |
Boehringer Ingelheim | Total Prescription Medicines | | | Euro | 10,101 | 10,891 | -7% |
Boehringer Ingelheim | Buscopan® | Butylscopolamine | OTC | Euro | 222 | 205 | 8% |
Boehringer Ingelheim | Dulcolax® | Bisacodyl | OTC | Euro | 200 | 191 | 5% |
Boehringer Ingelheim | Mucosolvan® | Ambroxol | OTC | Euro | 162 | 184 | -12% |
Boehringer Ingelheim | Pharmaton® | G115® Ginseng Extract | OTC | Euro | 136 | 139 | -2% |
Boehringer Ingelheim | Other Products | | | Euro | 717 | 754 | -5% |
Boehringer Ingelheim | Total Consumer HealthCare | | | Euro | 1,437 | 1,473 | -2% |
Boehringer Ingelheim | Total Animal Health | | | Euro | 1,130 | 1,070 | 6% |
Boehringer Ingelheim | Total Biopharmaceuticals | | | Euro | 501 | 449 | 12% |
Boehringer Ingelheim | Total Industrial Customers and Other Sales | | | Euro | 148 | 182 | -19% |
Boehringer Ingelheim | Total Sales | | | Euro | 13,317 | 14,065 | -5% |
Novo Nordisk | New-generation Insulin | Insulin | Diabetes | Danish crown | 658 | 143 | 360% |
Novo Nordisk | Modern Insulins (Insulin analogues) | Insulin | Diabetes | Danish crown | 41,537 | 38,153 | 9% |
Novo Nordisk | Human Insulins | Insulin | Diabetes | Danish crown | 10,298 | 10,869 | -5% |
Novo Nordisk | Victoza® | Liraglutide | Diabetes | Danish crown | 13,426 | 11,633 | 15% |
Novo Nordisk | Protein-Related Products | | | Danish crown | 2,333 | 2,412 | -3% |
Novo Nordisk | Oral Antidiabetic Products (OAD) | | | Danish crown | 1,728 | 2,246 | -23% |
Novo Nordisk | Total Diabetes Care | | | Danish crown | 69,980 | 65,456 | 7% |
Novo Nordisk | NovoSeven® | Recombinant Human Coagulation Factor VIIa | Blood Related Disorders | Danish crown | 9,142 | 9,256 | -1% |
Novo Nordisk | Norditropin® | Somatropin | Hormonal Disorders | Danish crown | 6,506 | 6,114 | 6% |
Novo Nordisk | Other Biopharmaceuticals | | | Danish crown | 3,178 | 2,746 | 16% |
Novo Nordisk | Total Biopharmaceuticals | | | Danish crown | 18,826 | 18,116 | 4% |
Novo Nordisk | Total | | | Danish crown | 88,806 | 83,572 | 6% |
Lundbeck | Cipralex® | Escitalopram Oxalate | Neuroscience/Mental Health | Danish crown | 4,647 | 5,933 | -22% |
Lundbeck | Azilect® | Rasagiline | Neuroscience/Mental Health | Danish crown | 1,497 | 1,392 | 8% |
Lundbeck | Xenazine® | Tetrabenazine | Rare Disease | Danish crown | 1,695 | 1,420 | 19% |
Lundbeck | Sabril® | Vigabatrin | Neuroscience/Mental Health | Danish crown | 716 | 530 | 35% |
Lundbeck | Onfi® | Clobazam | Neuroscience/Mental Health | Danish crown | 923 | 573 | 61% |
Lundbeck | Brintellix® | Vortioxetine | Neuroscience/Mental Health | Danish crown | 188 | | |
Lundbeck | Treanda® | Bendamustine Hydrochloride | Oncology | Danish crown | 212 | 129 | 64% |
Lundbeck | Ebixa® | Memantine Hydrochloride | Neuroscience/Mental Health | Danish crown | 1,058 | 2,096 | -50% |
Lundbeck | Other Pharmaceuticals | | | Danish crown | 1,985 | 1,701 | 17% |
Lundbeck | Other Revenues | | | Danish crown | 547 | 1,481 | -63% |
Lundbeck | Total | | | Danish crown | 13,468 | 15,255 | -12% |
Valeant Pharmaceuticals | Pharmaceuticals | | | Canadian dollar | 3,559.80 | 2,707.80 | 31% |
Valeant Pharmaceuticals | Devices | | | Canadian dollar | 1,629.40 | 845.3 | 93% |
Valeant Pharmaceuticals | OTC | | | Canadian dollar | 1,711.40 | 1,086.60 | 58% |
Valeant Pharmaceuticals | Branded and Other Generics | | | Canadian dollar | 1,203.00 | 1,000.60 | 20% |
Valeant Pharmaceuticals | Other Revenues | | | Canadian dollar | 159.9 | 129.3 | 24% |
Valeant Pharmaceuticals | Total | | | Canadian dollar | 8,263.50 | 5,769.60 | 43% |
Ipsen | Decapeptyl® | Triptorelin | Hormonal Disorders | Euro | 317 | 296.4 | 7% |
Ipsen | Somatuline® | Lanreotide | Hormonal Disorders | Euro | 288 | 239.6 | 17% |
Ipsen | Dysport® | Abobotulinumtoxin A | Others | Euro | 255 | 233 | 9% |
Ipsen | Nutropin® | Somatropin Recombinant | Hormonal Disorders | Euro | 59 | 56.1 | 5% |
Ipsen | Hexvix® | Hexaminolevulinate HCl | Oncology | Euro | 16 | 14.2 | 11% |
Ipsen | Increlex® | Mecasermin | Hormonal Disorders | Euro | 13 | 12.8 | 1% |
Ipsen | Total Specialty Care | | | Euro | 948 | 852.1 | 10% |
Ipsen | Smecta® | Diosmectite | Others | Euro | 121 | 117.7 | 2.70% |
Ipsen | Tanakan® | Ginkgo Biloba leaf extract | Cardiovascular | Euro | 63 | 62.6 | 0.60% |
Ipsen | Forlax® | Macrogol (aka polyethlene glycol) | Others | Euro | 39 | 39 | 0 |
Ipsen | Total Primary Care | | | Euro | 223 | 219.3 | 0.50% |
Ipsen | Others | | | Euro | 103.8 | 153.4 | -32% |
Ipsen | Net Sales | | | Euro | 1,274.80 | 1,224.80 | 4% |
Ipsen | Other Revenues | | | Euro | 57.6 | 57 | 1% |
Ipsen | Total Revenue | | | Euro | 1,332.40 | 1,281.80 | 4% |
Chugai Pharmaceuticals | Oncology | | | Yen | 188.9 | 172.4 | 10% |
Chugai Pharmaceuticals | Bone and Joint Diseases | | | Yen | 69.6 | 60.6 | 15% |
Chugai Pharmaceuticals | Renal Diseases | | | Yen | 44.7 | 48.9 | -9% |
Chugai Pharmaceuticals | Transplant, Immunoloty and Infectious Diseases | | | Yen | 20.8 | 18.8 | 11% |
Chugai Pharmaceuticals | Others | | | Yen | 25.6 | 28.6 | -10% |
Chugai Pharmaceuticals | Overseas | | | Yen | 74.3 | 61.1 | 22% |
Chugai Pharmaceuticals | Others | | | Yen | 13 | 10.9 | 19% |
Chugai Pharmaceuticals | Total Sales | | | Yen | 436.9 | 401.3 | 9% |
Chugai Pharmaceuticals | Royalties and Other Operating Income | | | Yen | 24.2 | 22.4 | 8% |
Chugai Pharmaceuticals | Total Revenues | | | Yen | 461.1 | 423.7 | 9% |
Otsuka Holdings | Abilify® | Aripiprazole | Neuroscience/Mental Health | Yen | 5,074.00 | 4,558.00 | 11% |
Otsuka Holdings | Oncology | | | Yen | 986 | 921 | 7% |
Otsuka Holdings | Clinical Nutrition | | | Yen | 815 | 820 | -1% |
Otsuka Holdings | Long-term Products | | | Yen | 390 | 521 | -25% |
Otsuka Holdings | Samsca® | Tolvaptan | Others | Yen | 208 | 153 | 36% |
Otsuka Holdings | Milestone | | | Yen | 149 | 115 | 30% |
Otsuka Holdings | Others | | | Yen | 1,212.00 | 924 | 31% |
Otsuka Holdings | Total Pharmaceuticals | | | Yen | 8,834.00 | 8,012.00 | 10% |
Otsuka Holdings | Total Nutraceuticals | | | Yen | 2,382.00 | 2,338.00 | 2% |
Otsuka Holdings | Total Consumer Products | | | Yen | 345 | 348 | -1% |
Otsuka Holdings | Others | | | Yen | 1,022 | 984 | 4% |
Otsuka Holdings | Corporate/Eliminations | | | Yen | 342 | 339 | 1% |
Otsuka Holdings | Total Consolidated | | | Yen | 12,241.00 | 11,343.00 | 8% |
Actavis | Namenda® Franchise | Memantine Hydrochloride | Neuroscience/Mental Health | Euro | 899 | | |
Actavis | Viibyrd®/ Fetzima® | Vilazodone hydrochloride | Neuroscience/Mental Health | Euro | 140 | | |
Actavis | Saphris® | Asenapine | Neuroscience/Mental Health | Euro | 70 | | |
Actavis | Other CNS | | | Euro | 49 | | |
Actavis | Total: CNS | | | Euro | 1,159 | - | |
Actavis | Delzicol® /Asacol HD® | Mesalamine | Gastrointestinal disorders | Euro | 564 | 150 | 275.50% |
Actavis | Linzess®/Costella® | Linaclotide | Gastrointestinal disorders | Euro | 174 | | |
Actavis | Carafate® /Sulcrate® | Sucralfate | Gastrointestinal disorders | Euro | 92 | | |
Actavis | Canasa® /Salofalk® | Mesalamine | Gastrointestinal disorders | Euro | 87 | | |
Actavis | Zenpep® , Ultrase® & Viokace® | Pancrelipase | Gastrointestinal disorders | Euro | 72 | | |
Actavis | Other Gastroenterology | | | Euro | 18 | | |
Actavis | Total: Gastroenterology | | | Euro | 1,007 | 150 | 570.20% |
Actavis | Lo Loestrin Fe® | norethindrone acetate and ethinyl estradiol | Sexual health | Euro | 277 | 63 | 337.80% |
Actavis | Minastrin® | norethindrone acetate and ethinyl estradiol | Sexual health | Euro | 218 | 56 | 291.20% |
Actavis | Estrace Cream® | Estradiol | Sexual health | Euro | 258 | 61 | 325.40% |
Actavis | Other Women's Health | | | Euro | 199 | 113 | 76.00% |
Actavis | Total: Women's Health | | | Euro | 952 | 293 | 225.20% |
Actavis | Bystolic® | Nebivolo | Antihypertensives | Euro | 293 | | |
Actavis | Daliresp® | Roflumilast | Respiratory disorders | Euro | 62 | | |
Actavis | Tudorza® | Aclidinium bromide | Respiratory disorders | Euro | 59 | | |
Actavis | Total: Cardiovascular,Respiratory & Acute Care | | | Euro | 413 | - | |
Actavis | Urology | | | Euro | 289 | 259 | 11.80% |
Actavis | Infectious diseases | | | Euro | 56 | | |
Actavis | Deramtology/ Established Brands | | | Euro | 755 | 361 | 109.30% |
Actavis | Total All Divisions | | | Euro | 4,631 | 1,063 | 335.90% |
Actavis | North American Generics and International | | | Euro | 6747.2 | 6418.2 | 5.10% |
Actavis | ANDA distribution | | | Euro | 1683.7 | 1196.9 | 40.70% |
Actavis | Total | | | Euro | 13,062 | 8677.6 | 50.50% |
Mitsubishi Tanabe | Remicade® | Infliximab | Immunology (Organ Transplant, Arthritis etc.) | United States dollar | 70.6 | 76.3 | -7% |
Mitsubishi Tanabe | Talion® | Bepostastine Besilate | Others | United States dollar | 16 | 13.7 | 17% |
Mitsubishi Tanabe | Ceredist® | Taltirelin | Neuroscience/Mental Health | United States dollar | 15.7 | 17.8 | -12% |
Mitsubishi Tanabe | Maintate® | Bisoprolol Fumarate | Cardiovascular | United States dollar | 14.1 | 15.5 | -9% |
Mitsubishi Tanabe | Venoglobulin IH® | Human Immunoglobulin | Others | United States dollar | 11.6 | 11.1 | 5% |
Mitsubishi Tanabe | Simponi® | Golimumab | Immunology (Organ Transplant, Arthritis etc.) | United States dollar | 10.5 | 9.4 | 12% |
Mitsubishi Tanabe | Kremezin® | Oral Absorptive Charcoal | Urology | United States dollar | 10.5 | 12.6 | -17% |
Mitsubishi Tanabe | Urso® | Ursodiol/Ursodeoxycholic acid | Others | United States dollar | 10.5 | 12.4 | -15% |
Mitsubishi Tanabe | Anplag® | Sarpogrelate Hydrochloride | Others | United States dollar | 8.3 | 11.2 | -26% |
Mitsubishi Tanabe | Depas® | Etizolam | Neuroscience/Mental Health | United States dollar | 8.1 | 9.8 | -17% |
Mitsubishi Tanabe | Lexapro® | Escitalopram | Neuroscience/Mental Health | United States dollar | 8 | 6.5 | 23% |
Mitsubishi Tanabe | Radicut® | Edaravone | Neuroscience/Mental Health | United States dollar | 7.4 | 10.9 | -32% |
Mitsubishi Tanabe | Tenelia® | Teneligliptin Hydrobromide Hydrate | Diabetes | United States dollar | 6.2 | 0.8 | 675% |
Mitsubishi Tanabe | Herbesser® | Diltiazem | Cardiovascular | United States dollar | 5.5 | 6.9 | -20% |
Mitsubishi Tanabe | Tanatril® | Imidapril | Cardiovascular | United States dollar | 4.6 | 6.2 | -26% |
Mitsubishi Tanabe | BIKEN Products [Vaccine] | | | United States dollar | 30.3 | 28.4 | 7% |
Mitsubishi Tanabe | Others | | | United States dollar | 86 | 92.2 | -7% |
Mitsubishi Tanabe | Ethical drugs domestic sales | | | United States dollar | 323.9 | 341.7 | -5% |
Mitsubishi Tanabe | Ethical drugs oversears sales | | | United States dollar | 23 | 22 | 5% |
Mitsubishi Tanabe | Contracted manufacturing products | | | United States dollar | 3.4 | 5.8 | -41% |
Mitsubishi Tanabe | Royalty from Gilenya® | Fingolimod | Neuroscience/Mental Health | United States dollar | 43.9 | 32.2 | 36% |
Mitsubishi Tanabe | Royalty from Invokana® | Canagliflozin | Diabetes | United States dollar | 9.8 | Undisclosed | |
Mitsubishi Tanabe | Royalty from Others | | | United States dollar | 6.7 | Undisclosed | |
Mitsubishi Tanabe | Royalty Income, etc. | | | United States dollar | 60.4 | 37.6 | 61% |
Mitsubishi Tanabe | OTC Products | | | United States dollar | 4 | 4.5 | -11% |
Mitsubishi Tanabe | Others | | | United States dollar | 0.4 | 1.1 | -64% |
Mitsubishi Tanabe | Total Pharmaceuticals | | | United States dollar | 415.1 | 412.7 | 1% |